Skip to content
Menu

Septerna, Inc. SEPN

Full chart Compare
Set alert

Price alert · SEPN

All alert types
39.20 USD -0.25 (-0.63%)

Regular-session close

39.20 0.00 0.00%

After hours · Nov 19, 4:27 PM ET

38.77 Day range 40.20
23.09 52-week range 52.34
YTD
+40.60%
1 year
+69.70%

5D -2.84 (-6.76%)

4042FriMonTueWedThu39.20
Market cap
1.86B
Revenue (ttm)
96.27M
Profit margin
-61.29%
EPS (ttm)
-1.29
Shares out
47.55M
Forward P/E
-25.81
YTD return
+40.60%
1-year return
+69.70%
50-day average
40.64
200-day average
33.36
Volume
209.02K
Avg volume
386.09K
Open
39.96
Previous close
39.45
Day's range
38.77 – 40.20
52-week range
23.09 – 52.34
Beta
2.20
Analysts
Strong Buy
Price target
59.56 (+51.9%)
Earnings date
Mar 8, 2027

Key statistics

Enterprise value
1.42B
Price / sales
19.36
Price / book
4.34
Revenue growth
-12.20%
Free cash flow
-7.81M
Total cash
478.60M
Total debt
21.99M
Return on equity
-14.45%
Short % of float
13.33%

Fundamental scorecard

5 of 25 checks passed on SEPN’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SEPN Revenue — quarterly 18.88M
SEPN Net income — quarterly -26.59M
SEPN EPS — quarterly -0.57

Earnings

SEPN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 8, 2027Dec 30, 2026-0.57———
Nov 9, 2026Sep 30, 2026-0.415-0.57-0.15-37.35%
Aug 10, 2026Jun 30, 2026-0.426-0.29+0.14+31.92%
May 12, 2026Mar 31, 2026-0.51-0.19+0.32+62.75%
Mar 9, 2026Dec 31, 2025-0.23-0.24-0.01-4.35%
Nov 10, 2025Sep 30, 20250.19-0.09-0.28-147.37%

Upgrades / downgrades

SEPN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026StifelmainBuyBuy
Nov 6, 2026GuggenheimmainBuyBuy
Nov 4, 2026Wells FargomainOverweightOverweight
Aug 19, 2026JP MorganmainOverweightOverweight
Aug 13, 2026Jones TradingmainBuyBuy
Aug 12, 2026Wells FargomainOverweightOverweight

About Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
septerna.com

News

Your note

Sign in to keep a note on SEPN — it syncs with the Stock Master app.

Insider holders

SEPN insider holders
InsiderRelationLatest transactionDateShares held
BHATT ELIZABETHPresidentConversion of Exercise of derivative securityOct 14, 2026174,209
EZEKOWITZ ALANDirectorSaleNov 10, 202635,600
FINER JEFFREYChief Executive OfficerConversion of Exercise of derivative securityNov 11, 2026833,909
KLEIN UWEOfficerConversion of Exercise of derivative securityAug 17, 2025127,533
LABRUCHERIE GILBERT M JRChief Financial OfficerSaleNov 15, 20260
LONG DANIEL DOfficerConversion of Exercise of derivative securityAug 31, 202696,412

Institution ownership

SEPN institution ownership
Holder% heldSharesValueReported
Trv Gp V, LLC 12.76%6,068,391237.88MSep 29, 2026
RA Capital Management, L.P.11.57%5,502,858215.71MSep 29, 2026
Driehaus Capital Management, LLC8.99%4,273,431167.52MSep 29, 2026
Trv Gp VI, LLC 8.86%4,211,659165.10MSep 29, 2026
Samsara BioCapital, LLC6.45%3,066,453120.20MSep 29, 2026
Goldman Sachs Group Inc6.35%3,018,431118.32MSep 29, 2026

Fund ownership

SEPN fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.95%927,66536.36MJun 29, 2026
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund1.91%907,72235.58MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.21%574,60422.52MSep 29, 2026
Driehaus Mutual Funds-Driehaus Small Cap Growth Fund0.88%417,85916.38MJun 29, 2026
LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund0.71%338,57913.27MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.55%261,54710.25MJun 29, 2026